Pharsight

Drugs that contain Oliceridine

1. Olinvyk patents expiration

OLINVYK's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11931350 TREVENA Opioid receptor ligands and methods of using and making same
Mar, 2032

(7 years from now)

US8835488 TREVENA Opioid receptor ligands and methods of using and making same
Mar, 2032

(7 years from now)

US9309234 TREVENA Opioid receptor ligands and methods of using and making same
Mar, 2032

(7 years from now)

US11077098 TREVENA Opioid receptor ligands and methods of using and making same
Mar, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9642842 TREVENA Opioid receptor ligands and methods of using and making same
Mar, 2032

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 30, 2025

NCE-1 date: 30 October, 2024

Market Authorisation Date: 30 October, 2020

Treatment: Management of acute pain by intravenous injection

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

OLINVYK family patents

Family Patents